COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light on the mechanisms of action, safety, and efficacy of CP using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCTs) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in uncertainty.
Article activity feed
-
-
-
SciScore for 10.1101/2021.09.07.21263194: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization Each study was analyzed for the following variables: NCT identifier, recruitment, randomization strategy, type of control arm, baseline patient status, median neutralizing antibody (nAb) titer in both recipients (before CCP transfusion) and CCP units, type of viral neutralization test (VNT), primary endpoint, signals of efficacy, and reasons for failure At the same date, the ClinicalTrials.gov database was searched for CCP RCTs worldwide having as status “completed”, “active, not yet recruiting” or “recruiting”. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources On … SciScore for 10.1101/2021.09.07.21263194: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization Each study was analyzed for the following variables: NCT identifier, recruitment, randomization strategy, type of control arm, baseline patient status, median neutralizing antibody (nAb) titer in both recipients (before CCP transfusion) and CCP units, type of viral neutralization test (VNT), primary endpoint, signals of efficacy, and reasons for failure At the same date, the ClinicalTrials.gov database was searched for CCP RCTs worldwide having as status “completed”, “active, not yet recruiting” or “recruiting”. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources On September 7, 2021, we searched PubMed (which is also indexing the medrXiv prepublishing server) for clinical trials of CCP in COVID19, focusing on RCTs and PSM studies only. PubMedsuggested: (PubMed, RRID:SCR_004846)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04359810 Completed Plasma Therapy of COVID-19 in Severely Ill Patients NCT04338360 Approved for marketing Expanded Access to Convalescent Plasma for the Treatment of … NCT04361253 Terminated Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plas… NCT04421404 Completed Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus… NCT04397757 Completed COVID-19 Convalescent Plasma for the Treatment of Hospitaliz… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
-